Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning
NCT ID: NCT05519774
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2022-08-01
2024-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors
NCT05048108
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca
NCT00756132
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
NCT05926024
Older Breast Cancer Patients: Risk for Cognitive Decline
NCT03451383
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy
NCT01382082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One other problem with previous brain fog research is that it has not included a diverse population. Therefore, what we think we know about brain fog may not be true for everyone with brain fog. The diverse population in the DMV area that Inova serves deserves to have their experiences represented in the research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status ≤ 2
* Patients diagnosed or with a history of breast cancer within the last 5 years.
* Life expectancy of at least 3 months
* Subject reports experiencing brain fog or cognitive impairment that the subject attributes to cancer or cancer therapy
* Able to sit for one hour and attend and respond to verbal and written instructions.
* Able to use a computer
Exclusion Criteria
* Severe hearing or visual impairment
* Unable to give informed consent
* Unable to read and write in English
* Those diagnosed with history of neurologic injuries or disorders (e.g. seizures, strokes, traumatic brain injury, brain surgery, neurodegenerative disorders) other than those attributable to cancer or cancer therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas at Dallas
OTHER
Inova Health Care Services
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Cohen, MD
Role: PRINCIPAL_INVESTIGATOR
Inova Health Care Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inova HCS
Falls Church, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U21-08-4519
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.